Kiadis Pharma AAQS 2024

Kiadis Pharma는 무엇을 하나요?

Kiadis Pharma NV was founded in 1997 in Amsterdam and is an innovative biotechnology company specializing in the development of cell therapies for the treatment of blood cancer diseases. The company is based in the Netherlands and is listed on the Euronext Amsterdam stock exchange. The business model of Kiadis is based on the development of therapies for patients with high medical needs, especially for individuals with severe blood cancer diseases for which there are no cure options. The company employs a proprietary platform technology that is based on the activation of T-cells for the therapy of cancer patients. Kiadis is currently developing various therapeutic approaches for the treatment of blood cancer diseases such as leukemia, lymphoma, and multiple myeloma. The company's main products are ATIR101 and ATIR201. ATIR101 is a cell therapy for patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) who require an allogeneic stem cell transplant. This therapy aims to reduce the risk of transplant rejection and graft-versus-host disease (GVHD), thereby increasing patients' chances of survival. ATIR201 is a therapy for the treatment of patients with multiple myeloma who require an allogeneic stem cell transplant. This therapy aims to reduce the risks of transplant rejection and GVHD, thereby increasing patients' chances of survival. Kiadis has also developed another platform technology called CytoSen, which is based on the activation of NK cells for the immunotherapy of cancer. The CytoSen technology aims to enhance the effectiveness of T-cell therapy by combining it with NK cells. Kiadis is continuously working to improve and expand its products and therapies. The company has a strong pipeline of product candidates at various stages of development targeting the treatment of leukemia, lymphoma, multiple myeloma, and other cancer diseases. The company has also entered into a partnership with Sanofi to accelerate the development of its therapies. Overall, Kiadis Pharma NV has an impressive history as an innovative company with a clear focus on the development of cell therapies for the treatment of blood cancer diseases. The company is dedicated to improving the lives of cancer patients and continuously works on the development of new therapies to improve the chances of survival and quality of life for cancer patients worldwide. Kiadis Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.